EPS Diluted (Annual) Chart

View EPS Diluted (Annual) for TEVA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View EPS Diluted (Annual) Chart
Start Trial

Historical EPS Diluted (Annual) Data

View and export this data back to 1992. Start Trial.
Date Value
December 31, 2025 1.222
December 31, 2024 -1.456
December 31, 2023 -0.4983
December 31, 2022 -2.195
December 31, 2021 0.377
December 31, 2020 -3.669
December 31, 2019 -0.9186
December 31, 2018 -2.342
December 31, 2017 -16.39
December 31, 2016 0.071
December 31, 2015 1.820
December 31, 2014 3.551
December 31, 2013 1.494
December 31, 2012 2.249
December 31, 2011 3.078
December 31, 2010 3.670
December 31, 2009 2.232
Date Value
December 31, 2008 0.7527
December 31, 2007 2.381
December 31, 2006 0.6902
December 31, 2005 1.590
December 31, 2004 0.4999
December 31, 2003 1.196
December 31, 2002 0.7609
December 31, 2001 0.5086
December 31, 2000 0.2856
December 31, 1999 0.4845
December 31, 1998 0.5464
December 31, 1997 0.00
December 31, 1996 0.00
December 31, 1995 0.00
December 31, 1994 0.00
December 31, 1993 0.00
December 31, 1992 0.00

Earnings per Share Definition

Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.

Read full definition.

EPS Diluted (Annual) Range, Past 5 Years

View EPS Diluted (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EPS Diluted (Annual) Benchmarks

View EPS Diluted (Annual) Benchmarks
Start Trial
Eli Lilly & Co. 22.95
Bristol Myers Squibb Co. 3.460
RedHill Biopharma Ltd. -0.1008
Johnson & Johnson 11.03
Merck & Co., Inc. 7.281